HLN vs PBH

For growth investors, Prestige Consumer Healthcare Inc.

(PBH) is the stronger pick with 1. 1% revenue growth year-over-year, versus -4. 0% for Haleon plc (HLN). Prestige Consumer Healthcare Inc. (PBH) offers the better valuation at 12. 7x trailing P/E (12. 0x forward), making it the more compelling value choice. Analysts rate Haleon plc (HLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Prestige Consumer Healthcare Inc.

(PBH) is the cheapest at 12. 7x versus Haleon plc at 19. 0x. On forward P/E, Prestige Consumer Healthcare Inc. is actually cheaper at 12. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Prestige Consumer Healthcare Inc. wins at 1. 33x versus Haleon plc's 2. 63x — a reasonable growth-adjusted valuation.

Over the past 5 years, Haleon plc (HLN) delivered a total return of +31.

7%, compared to +18. 4% for Prestige Consumer Healthcare Inc. (PBH). Over 10 years, the gap is even starker: HLN returned +31. 7% versus PBH's -3. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haleon plc (HLN) is the lower-risk stock at 0.

06β versus Prestige Consumer Healthcare Inc. 's 0. 53β — meaning PBH is approximately 775% more volatile than HLN relative to the S&P 500. On balance sheet safety, Haleon plc (HLN) carries a lower debt/equity ratio of 52% versus 57% for Prestige Consumer Healthcare Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Prestige Consumer Healthcare Inc.

(PBH) is pulling ahead at 1. 1% versus -4. 0% for Haleon plc (HLN). On earnings-per-share growth, the picture is similar: Haleon plc grew EPS 12. 5% year-over-year, compared to 2. 9% for Prestige Consumer Healthcare Inc.. Over a 3-year CAGR, PBH leads at 1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Prestige Consumer Healthcare Inc.

(PBH) is the more profitable company, earning 18. 9% net margin versus 15. 1% for Haleon plc — meaning it keeps 18. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBH leads at 29. 6% versus 22. 4% for HLN. At the gross margin level — before operating expenses — HLN leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Prestige Consumer Healthcare Inc. (PBH) is the more undervalued stock at a PEG of 1. 33x versus Haleon plc's 2. 63x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Prestige Consumer Healthcare Inc. (PBH) trades at 12. 0x forward P/E versus 22. 2x for Haleon plc — 10. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PBH: 20. 9% to $66. 00.

In this comparison, HLN (1.

9% yield) pays a dividend. PBH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 1. 9% yield). Both have compounded well over 10 years (HLN: +31. 7%, PBH: -3. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HLN is a mid-cap quality compounder stock; PBH is a small-cap deep-value stock. HLN pays a dividend while PBH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.